尿激酶溶栓治疗发病2h内急性ST段抬高型心肌梗死的疗效  

Curative Effect of Urokinase Thrombolysis on the Acute ST-Segment Elevation Myocardial Infarction on the Onset within Two Hours

作　　者：张锐[1] 李文超[1] 

机构地区：[1]新疆医科大学第一附属医院急诊科,新疆乌鲁木齐830054

出　　处：《中外医疗》2015年第10期101-102,共2页China & Foreign Medical Treatment

摘　　要：目的使用尿激酶溶栓治疗发病2 h内急性ST段抬高型心肌梗死,对其治疗有效性及安全性进行客观评价。方法选取在该院接受诊治的96例2 h内急性ST段抬高型心肌梗死的患者,按照随机数字表法分成两组进行比较,对照组使用常规药物治疗,观察组使用尿激酶溶栓进行治疗;对比分析两组患者接受治疗后病情控制情况及治疗有效性与安全性。结果治疗完成时,明显看出使用尿激酶溶栓治疗的观察组患者再通率高于对照组,差异有统计学意义(<0.05);同时对治疗期间患者出现不良反应或并发症的情况进行记录对比,对照组中并发症发生率显著高于观察组,差异具有统计学意义(<0.05)。结论尿激酶溶栓对治疗2 h内急性ST段抬高型心肌梗死患者具有较好的治疗效果及极高的安全性,有利于帮助患者早日恢复健康并提高患者的生存质量,在临床使用价值较高。Objective To make the objective evaluation on the effectiveness and security by using urokinase thrombolysis to treat the acute ST-segment elevation myocardial infarction on the onset within two hours. Method 96 patients with the acute ST-segment elevation myocardial infarction on the onset within two hours in our hospital were selected and divided into control group and observation group according to the random number table. The control group were treated with conventional medicines while the observation group were treated with urokinase thrombolysis. Upon the treatment, the control of disease, effectiveness and security of two groups were observed.Result The recanalization rate of the observation group in receiving the urokinase thrombolysis treatment was clearly higher than that of the control group（ 〈0.05）. To record and compare the adverse reaction or medical complications during the treatment period, the complication rate of the control group was significantly higher than that of the observation group（P〈0.05）. Conclusion There was the better curative effect and higher security for the patients with the acute ST-segment elevation myocardial infarction on the onset within two hours to achieve the urokinase thrombolysis treatment, which could be helpful for the patients to recover soon and improve the quality of life . Its clinical value is higher.

关 键 词：尿激酶溶栓 ST段抬高型心肌梗死 有效性及安全性 观察评价 

分 类 号：R542.22[医药卫生—心血管疾病]